The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
If chronic Hepatitis B or C has rendered you incapable of performing any work, Social Security disability benefits may provide a safety net. Understanding the guidelines for disability will help those truly in need to better work their way through an intensive application process.
Continue reading »A recent, popular television show educated viewers on the importance of raising glutathione levels. Although the practical suggestions given were accurate, there is much more to know about this topic. Especially important for Hepatitis C patients, two supplements demonstrate unparalleled glutathione-boosting power.
Continue reading »The changes in a woman's immune system during pregnancy can increase susceptibility to many pathogens, including a resurgence of latent ones. Research shows that even if a woman is just a carrier of Hepatitis B, liver issues can flare after she gives birth to a child.
Continue reading »Find out why a common indicator of cardiovascular disease is inaccurate for those with chronic Hepatitis C infection. February is American Heart Month.
Continue reading »A United Kingdom charity is spearheading the development of a large network of patients and research to better understand, treat and prevent the Hepatitis C virus.
Continue reading »Most of us know that alcohol is not good for someone with the Hepatitis C virus. In addition to alcohol's ability to speed up the progress of liver disease, there is now proof that drinking during antiviral therapy nullifies the effectiveness of Hepatitis C treatment.
Continue reading »A genetic variant appears to protect against anemia brought on by Hepatitis C antiviral treatment.
Continue reading »Likely due to its ability to dramatically improve the Hepatitis C cure rate, Vertex's telaprevir will get a priority review by the FDA.
Continue reading »Two new drugs expected to enter the market soon appear to nearly double the success rate of Hepatitis C treatment. As a result of this therapeutic improvement, the age group most at risk for the Hepatitis C virus may be routinely screened for this infection.
Continue reading »Peregrine Pharmaceuticals, Inc. has started a Phase II clinical trial to determine if bavituximab plus ribavirin elicits an early virologic response in people with previously untreated genotype-1 Hepatitis C.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
